CHCeline Hoyek

Celine Hoyek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Celine Hoyek has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

    by Celine Hoyek, Cody Eslinger, Angelo Pirozzi, Mojun Zhu, Mitesh Borad, Christina Wu, Daniel Ahn, Tanios Bekaii-Saab, Mohamad Bassam Sonbol

    Background: Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle) is associated with significant cumulative toxicity, leading to frequent dose reductions and treatment discontinuation in real-world practice. A biweekly GA regimen, consisting in administering chemotherapy on days 1 and 15 of a 28-day cycle, has been explored as an alternative to improve tolerability while maintaining efficacy. This systematic review evaluates the real-world efficacy and safety of biweekly GA for advanced or mPDAC. Methods: A comprehensive search of PubMed, Embase, Web of Science, Scopus, and Cochrane databases was performed from inception through February 2026 following PRISMA guidelines. Retrospective and prospective studies comparing biweekly GA to the standard schedule were included. Two reviewers independently performed study selection, data extraction, and risk of bias assessment. Primary outcomes were overall survival (OS) and toxicity, secondary outcome was progression-free survival (PFS). Risk of bias was assessed using the ROBINS-I tool. Meta-analysis could not be performed due to data heterogeneity, therefore findings were summarized descriptively. Results: Five retrospective studies met inclusion criteria. In studies evaluating standard-dose biweekly GA (gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m²), median OS ranged from 9.1-10 months and median PFS from 4.8-5.4 months, comparable to historical data from the phase III MPACT trial and the control arm of the NAPOLI 3 trial. A large population-based study of elderly patients (n=1,303) reported shorter OS (7.6 months) with modified schedules, due to lower baseline performance status. Across studies, biweekly GA showed a favorable safety profile, with lower rates of grade ≥3 neutropenia, febrile neutropenia, and peripheral neuropathy compared to standard dosing. Conclusion: Biweekly GA appears to be a feasible and well-tolerated dosing strategy, with survival outcomes overlapping historical weekly GA cohorts in advanced or mPDAC. While prospective randomized trials are needed, the reproducibility of efficacy and tolerability findings across real-world cohorts supports biweekly GA as a viable alternative.

  • Open Access

    Homologous Recombination Deficiency as a Biomarker for Chemoimmunotherapy Benefit in Advanced Biliary Tract Cancer: A Multicenter Retrospective Cohort Study

    by Oluseyi Abidoye, Heidi Kosiorek, Taro Shibuki, Angelo Pirozzi, Celine Hoyek, Abdullah Alsulaiman, Naohiro Okano, Ryne Ramaker, Cody Eslinger, Binbin Zheng-Lin, et al.

    Background: Biliary tract cancers (BTC) are aggressive malignancies with limited treatment options. Homologous recombination deficiency (HRD) may confer increased immunogenicity and potentially augment responsiveness to immune checkpoint inhibitor-based chemoimmunotherapy (CIO), but its predictive value for immunotherapy benefit in BTC remains poorly characterized.Methods: This multicenter retrospective study included 998 patients with advanced BTC treated between 2012 and 2024. HRD status was determined via genomic sequencing of tumor tissue or circulating tumor DNA. Patients were stratified by HRD status and first-line treatment ( Chemotherapy (CT) alone vs. CIO). Primary endpoints were progression-free survival (PFS) and overall survival (OS) analyzed by Kaplan-Meier estimates while predictors were assessed through univariate and multivariate Cox regression.Results: Of 998 patients, 179 (17.9%) were HRD-positive, of whom 15.1% received CIO. The most commonly HRR alterations were ATM (38.5%), BRCA2 (23.5%) and BRCA1 (16.2%). ORR was higher with CIO vs. CT in both HRD- (35.2% vs. 22.5%; p=0.008) and HRD+ patients (51.9% vs. 25.8%; p=0.01), but this did not translate into survival benefit. In HRD+ patients, CIO was associated with worse OS than CT (13.4 vs. 22.5 months; HR 2.07, 95% CI 1.22–3.54; p=0.006). Among BRCA1/2-mutant patients, CT alone yielded better OS than CIO (33.6 vs. 24.8 months; HR 2.90; p=0.045). Multivariable analysis revealed HRD status did not independently predict OS while CIO use (HR 1.58, 95% CI 1.07–2.32; p=0.020) was associated with decreased OS.Conclusions: Adding immunotherapy to chemotherapy did not improve survival in HRD+ BTC patients. These findings are hypothesis-generating and raise the possibility that HRD+ status is associated with a lack of added benefit from IO to CT, underscoring the need for prospective biomarker-driven trials to refine treatment strategies in BTC.

  • Successful Management of BRAF V600E–Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy

    by Celine Hoyek, Angelo Pirozzi, Kelley Rone, Christina Wu, Jeremy Jones, Tanios Bekaii-Saab

    The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer (mCRC). However, its safety and efficacy in patients with significant liver dysfunction remains unclear and, as such, patients are often excluded from pivotal clinical trials. This report presents a case of BRAF V600E–mutated mCRC presenting with extensive hepatic involvement and liver dysfunction. Despite the absence of guidelines, the patient was initiated on full-dose encorafenib, cetuximab, and FOLFOX. He experienced a rapid clinical and biochemical response, with near-normalization of liver enzymes after cycle 1, and complete functional recovery by cycle 3. Treatment was well tolerated, with no significant adverse events throughout 9 cycles. He subsequently transitioned to maintenance 5-FU, cetuximab, and encorafenib. Posttreatment blood-based next-generation sequencing revealed no residual actionable mutations. The patient then successfully underwent complete surgical resection of his primary tumor and metastatic disease with negative margins. This case highlights the importance of considering encorafenib-based therapy in select patients with BRAF V600E–mutated mCRC in the setting of compromised liver function.

  • Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab

    by Naohiro Okano, Angelo Pirozzi, Conor O'DOnnell, Masato Hayashi, Pedro Luiz Serrano Uson Junior, Celine Hoyek, Oluseyi Abidoye, Cody Eslinger, Binbin Zheng-Lin, Natalie M. Elliott, et al.

    PURPOSE: For patients with advanced biliary tract cancer (BTC), cancer-related time spent in health care systems, time toxicity, represents a critical but understudied burden affecting quality of life. This study aimed to quantify time toxicity in patients receiving first-line systemic therapy and evaluate whether the addition of durvalumab to gemcitabine plus cisplatin (GC) increases health care contact time. METHODS: This international, multicenter, retrospective cohort study included patients with advanced BTC seen between January 2019 and April 2024 at Mayo Clinic Enterprise (US), and between January 2021 and April 2024 at Kyorin University Hospital (Japan), and Hospital Israelita Albert Einstein (Brazil). Patients received GC plus durvalumab (GCD) or GC. Time toxicity was recorded from treatment initiation until discontinuation or last follow-up during first-line systemic therapy. Multiple regression analysis identified factors associated with high time toxicity. RESULTS: Among 193 patients (102 GCD, 91 GC; median age 65 years; 50% male; 49% Eastern Cooperative Oncology Group performance status [PS] 0), median time on treatment (TOT) was 156 days (95% CI, 122 to 190). The median proportion of total time toxicity was 14.4% (IQR, 10.9-20.6). Planned visits accounted for 11.9%, while unplanned visits were infrequent (1.8%). Time toxicity strongly correlated with TOT ( r = 0.824) and progression-free survival ( r = 0.827). Despite longer treatment in the GCD group than the GC group (212 v 134 days; P = .027), total time toxicity was similar (27 v 18 days; P = .19). Younger age and poor PS were independent factors of higher time toxicity. CONCLUSION: Time toxicity represents a meaningful metric that allows for more comprehensive integration of the net benefit in patients with advanced BTC with a limited lifespan.

  • Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis

    by Celine Hoyek, Syed Arsalan Ahmed Naqvi, Oudai Sahvan, Fares Jamal, Kunwer Sufyan Faisal, Angelo Pirozzi, Surabhi Pathak, Diana Almader-Douglas, Mitesh J. Borad, Christina Wu, et al.


  • Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review

    by Celine Hoyek, Binbin Zheng-Lin, Jennah J. Bauernfeind, Omar Hussain Al-Ahmad, Tanios Bekaii-Saab, Sakti Chakrabarti, Sawsan Rashdan, Mohamad B. Sonbol

    PURPOSE: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various malignancies. However, the high cost of these therapies limits access for much of the global population. This systematic review aims to evaluate the efficacy of low-dose ICIs compared with standard doses in different malignancies, addressing financial and access barriers in global cancer care. METHODS: We conducted a systematic review of studies comparing the efficacy of low-dose versus standard-dose ICI regimens in advanced solid tumors. A comprehensive search was performed across multiple electronic databases, including retrospective and prospective studies. Excluded were animal studies, editorials, conference papers, book chapters, and other immunotherapy modalities. Outcomes assessed included overall survival (OS), progression-free survival, and objective response rate. Results were summarized descriptively due to study heterogeneity. RESULTS: From 1,010 screened articles, four studies with 435 Asian patients were included, covering a variety of solid tumors. All included studies were with a low quality of evidence and a high risk of bias due to retrospective design. Two studies used weight-based dosing (pembrolizumab <2 mg/kg and nivolumab <2.15 mg/kg), showing similar OS to standard dosing in non–small cell lung cancer (NSCLC) and renal cell carcinoma, respectively. Flat dose regimens in two studies (nivolumab 20 mg or 100 mg once every 3 weeks and pembrolizumab 100 mg once every 3 weeks) also demonstrated comparable OS in NSCLC. CONCLUSION: Low-dose ICIs may offer equivalent clinical benefits to standard dosing, potentially reducing costs and expanding access in developing countries. Although awaiting more representative randomized clinical trials, weight-based ICI regimens could be a viable alternative in low- and middle-income countries.


  • Open Access

    Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

    by Celine Hoyek, Angelo Pirozzi, Jeremy Jones, Lorenza Rimassa, Mohamad B Sonbol, Tanios Bekaii-Saab

    Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all


  • Open Access

    Peposertib as a radiosensitizing agent in the treatment of locally advanced rectal cancer

    by Celine Hoyek, Binbin Zheng-Lin, Tanios Bekaii-Saab

    Peposertib as a radiosensitizing agent in the treatment of locally advanced rectal cancer